Additionally, we evaluated tumor infiltrating lymphocytes and predictive immune markers for immunotherapy of the signature and found that patients in low risk cohorts possessed higher measures of CD8 T cells, macrophage M1, as well as other immune cells related to infiltration, which indicated that this five‐gene signature might have potential as immunotherapy target thereby warranting further analyses. This evidence concerns the gene CD8A and neoplasm.